1. |
茹建华, 吴伯镛. 细胞色素P450酶与用药选择[J]. 医药导报, 2005, 24(3): 241-242.
|
2. |
杨海峰, 江善祥. 苯巴比妥对鸡肝微粒体CYP450活性的影响[J]. 江西农业学报, 2010, 22(5): 138-140.
|
3. |
毛萍, 乔定君, 马欣荣. 细胞色素P450和医学[J]. 中国抗生素杂志, 2011, 36(2): 93-101.
|
4. |
崔颖, 张永旺. P450酶的研究进展[J]. 中国新技术新产品, 2009(16): 7-8.
|
5. |
范岚, 彭向东, 郭志华, 等. CYP450氧化还原酶的遗传多态对药物代谢的影响[J]. 中国药理学通报, 2009, 25(9): 1131-1133.
|
6. |
陈杰, 陈孝. 细胞色素P450基因多态性对药物疗效和安全性的影响[J]. 药品评价, 2010, 7(4): 58-62.
|
7. |
Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes[J]. Curr Drug Metab, 2009, 10(6): 567-578.
|
8. |
徐田雪, 杨信怡, 赵昆, 等. 药物代谢酶细胞色素P450 2D6的遗传多态性研究进展[J]. 中国抗生素杂志, 2009, 34(7): 385-391.
|
9. |
孙宜锋, 方渡. 新型细胞色素P450氧化酶的发现与筛选[J]. 中国医药生物技术, 2011, 6(3): 214-217.
|
10. |
张慧锋, 王月鹏, 李妍. 细胞色素P450的研究进展[J]. 吉林医药学院学报, 2005, 26(3): 174-177.
|
11. |
Hersh EV, Moore PA. Drug interactions in dentistry: the importance of knowing your CYPs[J]. J Am Dent Assoc, 2004, 135(3): 298-311.
|
12. |
Chhun S, Verstuyft C, Rizzo-Padoin N, et al. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers[J]. Br J Clin Pharmacol, 2009, 68(2): 226-237.
|
13. |
Galetin A, Gertz M, Houston JB. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions[J]. Drug Metab Pharmacokinet, 2010, 25(1): 28-47.
|
14. |
Vandenbrink BM, Isoherranen N. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition[J]. Curr Opin Drug Discov Devel, 2010, 13(1): 66-77.
|
15. |
Zhang L, Wei MJ, Zhao CY, et al. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes[J]. Acta Pharmacol Sin, 2008, 29(12): 1507-1514.
|
16. |
Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin[J]. Br J Clin Pharmacol, 2000, 50(4): 285-295.
|
17. |
Grönlund J, Saari T, Hagelberg N, et al. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone[J]. J Clin Pharmacol, 2010, 50(1): 101-108.
|
18. |
邹文, 周文, 欧扬. 琥乙红霉素和阿司匹林合用对大鼠肝脏细胞色素P450酶的影响[J]. 中国医院药学杂志, 2008, 28(7): 505-508.
|
19. |
刘荔, 刘嵘, 吴畅烜, 等. 乳酸卡德沙星对大鼠肝P450酶活性的影响[J]. 中国药科大学学报, 2007, 38(2): 144-148.
|
20. |
Granfors MT, Backman JT, Neuvonen M, et al. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism[J]. Clin Pharmacol Ther, 2004, 76(6): 598-606.
|
21. |
Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype[J]. Br J Clin Pharmacol, 2009, 68(6): 906-915.
|
22. |
Shon JH, Yeo CW, Liu KH, et al. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants[J]. J Clin Pharmacol, 2010, 50(2): 195-204.
|
23. |
Uttayamakul S, Likanonsakul S, Manosuthi W, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults[J]. AIDS Res Ther, 2010, 7: 8.
|
24. |
Kim SH, Kim SH, Bahn JW, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis[J]. Pharmacogenomics, 2009, 10(11): 1767-1779.
|
25. |
Shin KH, Kim BH, Kim TE, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study[J]. Clin Ther, 2009, 31(12): 3009-3020.
|
26. |
Skerjanec A, Wang J, Maren K, et al. Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral Iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers[J]. J Clin Pharmacol, 2010, 50(2): 205-213.
|